Dermatology Update 2016
SESSIONS & ABSTRACTS
Montréal, Le Centre Sheraton - NOVEMBER 3-6, 2016
Treatment of Plaque Psoriasis in Children and Adolescents with Etanercept
In some patients, the development of psoriasis symptoms can occur before adulthood. During the formative developmental years of childhood and adolescence, the presence of psoriasis and its associated comorbidities can result in a substantial negative impact on QoL, especially in regards to emotional and school functioning. Despite the devastating impact of this disease on children and adolescents, access to effective systemic treatments is limited.
Etanercept, a soluble tumour necrosis factor receptor fusion protein, is approved in Canada to treat moderate to severe plaque psoriasis in adults, but currently not in children and adolescents. Interestingly, etanercept is approved for the treatment of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients aged 4-17. This plenary session will discuss the results of a 48-week, randomized, double-blind, placebo-controlled parent study and a 264-week open-label extension (OLE) to examine safety and efficacy of etanercept in pediatric patients 4-17 years of age with moderate to severe plaque psoriasis. This study represents the largest published study with the longest follow-up of any biologic for the treatment of psoriasis in the pediatric population. Also highlighted in this session will be clinical responses in psoriasis patients discontinued from and restarted on etanercept therapy, as the ability to recapture treatment responses after discontinuation of therapy may be of particular importance in children and adolescence.